| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10918799 | Radiotherapy and Oncology | 2013 | 8 Pages |
Abstract
These results warrant further investigation into the possible clinical benefit of CD44+/CD24â as a predictive marker in EC patients for the response to chemoradiation.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Justin K. Smit, Hette Faber, Maarten Niemantsverdriet, Mirjam Baanstra, Johan Bussink, Harry Hollema, Ronald P. van Os, John Th. M. Plukker, Robert P. Coppes,